In another study, selinexor treatment was found to effectively reduce tumor growth in ten KRAS-mutant NSCLC PDXs irrespective of the type of KRAS mutation, indicating a general dependency of KRAS-mutant cancers on XPO1 (24). This evidence concerns the gene KRAS and cancer.